Clinical Trial Update: Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with CAPOX for advanced biliary tract cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Biliary Tract Neoplasms
• Cholangiocarcinoma
• Gallbladder Cancer
• Liver Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-15